Evolus, Inc.

Good afternoon, everyone, and thank you for standing by. Welcome to EVOLUS' second quarter 2024 earnings conference call. As a reminder, today's conference is being recorded and webcast live. All participants are on a listen-only mode. After the speaker's remarks, there will be a question-and-answer session. I would now like to turn the conference over to your hosts, Nurag Sekharian, Vice President and Head of Global Investor Relations and Corporate Communications. Please go ahead.

Thank you, Operator, and welcome to everyone joining us on today's call to review Evelis' second quarter 2024 financial results. Our second quarter 2024 press release is now on our website at evelis.com. With me today are David Modazzetti, President and Chief Executive Officer, and Sandra Beaver, Chief Financial Officer. Rui Avalar, Chief Medical Officer and Head of R&D, is also with us for the Q&A portion of the call. Before we begin our discussion, I'd like to note that during our call, our prepared remarks will include forward-looking statements within the meaning of United States securities laws, and management may make additional forward-looking statements in response to your questions. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which may affect the company's business, strategy, operations, or financial performance. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this call, and the company undertakes no obligation to update or review any estimate, projection, or forward-looking statement except as required by law. These forward-looking statements are based on estimates and assumptions that, although believed to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. A detailed discussion of the risks and uncertainties that the company faces is contained in its annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Additionally, today's discussion will include non-GAAP financial measures, which should be considered in addition to and not as a substitute for or in isolation from our GAAP results. A reconciliation of GAAP to non-GAAP results may be found in our earnings release, which was furnished with our Form 8K, filed today with the SEC, and on our Investor Relations website at eveless.com. Following the conclusion of today's call, a replay will be available on our website at eveless.com. With that, I'll turn the call over to our CEO, David Modazzetti.

Thank you, Nurag. Good afternoon, everyone. Thank you for joining us on our second quarter 2024 earnings conference call. This is a very exciting time for Ebolus as we've now completed the first half of 2024 and have demonstrated continued market share gains with GVO. This year is focused on our flagship product while we prepare to expand our portfolio. We are incredibly pleased with the continued momentum in our business, which is clearly reflected in our second quarter results announced earlier today. In the second quarter, we achieved an important milestone, profitability, and Javot's market share increased to 13%. We accomplished this with a single product while investing in the launch of our filler line. Our focus is delivering exceptional results, and our unique structure and value proposition are operating at a high level. Our reported revenue of 66.9 million in the second quarter represents 36% growth over the prior year. The combination of the continued strength of our execution and the momentum we have built during the first half of the year give us the confidence to raise our full year 2024 net revenue guidance to between 260 million and 270 million. This updated guidance equates to 34% growth at the top end and is several degrees of magnitude above the estimated growth rate for our category. Importantly, this is a brand that continues to grow at over 30% in its fifth year on the market, signaling the quality of the GEVO brand and the strength of our unique business model. We continue to build loyalty and trust with our customers. We have a unique position as the only dedicated cash pay aesthetic toxin company and a differentiated approach to building a performance beauty brand. We remain focused on the younger generation and helping practices grow. Our differentiation is evident in the continued growth in new purchasing accounts, increasing by 770 in the quarter. This brings our total number of customers purchasing since launch to approximately 14,000. which is approaching 50% penetration of the market. Our Evelis consumer loyalty program is also thriving and on track to surpass 1 million consumers in the program by year end. The underlying strength of our business and our strategic focus are just part of the story. Internally, we are preparing for a transformative year in 2025. This preparation starts with the commercialization of our novel dermal filler line, In June, we submitted our pre-market approval application to the FDA for Evelisse Lift and Evelisse Smooth. In Europe, regulatory approvals for the esteemed dermal filler products are anticipated later this year, and we remain on track for U.S. and international launch in 2025. Our commercialization plans are well underway, and we will share more details at our Investor Day in September. Internationally, we continue to make significant progress with NuSiva. We continue to expand our international business with a focus on deeper penetration in the UK, Germany, and Italy, while broadening our global footprint by commercially launching in Spain and Australia. With these recent launches, we are now operating in all the major markets needed to deliver our 2028 guidance. The toxin market remains strong, and we are well-positioned to benefit from the growing shift towards Evalis and the GIVO brand. GIVO's brand recognition, clinical performance, and high satisfaction profile are well-positioned for new consumers entering the category. This positioning will allow us to continue capturing demand while we actively prepare to integrate our novel dermal filler line, Evalis. These efforts collectively keep us on pace to our long-term revenue target of at least $700 million by 2028. Our differentiated go-to-market strategy continues to set us apart, and I look forward to sharing more updates as we progress. Now I'll turn it over to Sandra, who will cover the financials.